Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Astal Laboratories Ltd (512600)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 512600 NSE: Pharmaceuticals & Drugs | Small Cap | Astal Laboratories Share Price
₹58.47 7.22 (14.09%)
As on 04-Nov'26 16:59
Astal Laboratories Ltd (512600)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 512600 NSE: Pharmaceuticals & Drugs | Small Cap | Astal Laboratories Share Price
₹58.47 7.22 (14.09%)
As on 04-Nov'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹224 Cr.
Current Price
₹58.5
52-Week Low / High
₹50 / 100
TTM EPS
₹3.4
TTM Sales
₹250 Cr.
Book Value per Share
₹79.3
P/E Ratio
15.26
Higher than its 5-year historical median
Industry PE
52.9
Price to Book (P/B)
0.65
Lower than its 5-year historical median
Price to Sales (P/S)
0.90
Lower than its 5-year historical median
EV/EBITDA
13.00
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
8.08%
Return on Capital Employed (ROCE)
9.15%
Return on Assets (ROA)
5.05%
Operating Profit Margin
8.3%
Net Profit Margin
5.88%
Gross Profit Margin
7.6%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
142.88%
Operating Profit Growth (1 Year)
-
62.52%
Net Profit Growth (1 Year)
-
64.73%
Asset Quality
Promoter Holding
4.59%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹304 Cr.
Equity
₹43.8 Cr.
Face Value
₹10
All Time Low / High
₹4.05 / 131.70
Check Before You Invest
Quality
Locked
Login to view analysis.
Valuation
Locked
Login to view analysis.
Price Trend
Locked
Login to view analysis.
Is Astal Laboratories Ltd a good quality company?
Astal Laboratories Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Astal Laboratories Ltd performance compare with that of its Peers?
Revenue growth of Astal Laboratories Ltd vs industry peers?
Astal Laboratories Ltd revenue CAGR is 20.50%, compared to the industry median CAGR of %, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Astal Laboratories Ltd?
Promoters hold 4.59% of the Astal Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Astal Laboratories Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 10.9% based on the current price.
10 Year X-Ray : Login to view analysis.
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Astal Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0.2% | -0.1% | -1.4% | -0.5% | 0.2% | -0.3% | 0.6% | 7.6% | 34.8% | 6.3% | - |
| Value Creation Index ⓘ | -1.0 | -1.0 | -1.1 | -1.0 | -1.0 | -1.0 | -1.0 | -0.5 | 1.5 | -0.6 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 3.4 | 23.7 | 64.2 | 156 | 170 |
| Sales YoY Gr. | - | NA | NA | NA | NA | NA | NA | 589.5% | 171.6% | 142.9% | - |
| Adj EPS ⓘ | 0 | -0 | -0.2 | -0.1 | 0 | -0 | 0 | 0.8 | 9.1 | 1.9 | 2.2 |
| YoY Gr. | - | -300% | NA | NA | NA | -250% | NA | 1900% | 1035% | -78.9% | - |
| BVPS (₹) ⓘ | 13.3 | 13.3 | 13 | 13 | 13 | 13 | 13 | 23.7 | 32.8 | 77 | 76.5 |
| Adj Net Profit ⓘ | 0 | -0 | -0.1 | -0 | 0 | -0 | 0 | 0.8 | 8.9 | 8.1 | 10 |
| Cash Flow from Ops. ⓘ | -0.3 | -0.3 | -0.3 | -0.2 | -0.2 | -0.3 | -1.4 | -5.6 | -12.5 | -3.1 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.1 | -1.1 | -3.9 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 257% | 142.9% | ||||
| Adj EPS ⓘ | 79.4% | 149.2% | 263.4% | -78.9% | ||||
| BVPSⓘ | 21.6% | 42.8% | 81% | 134.7% | ||||
| Share Price | 12.2% | 43.3% | 20.2% | -39.7% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0.1 | -0.1 | -1.6 | -0.5 | 0.1 | -0.3 | 0.3 | 5.5 | 30.1 | 4.5 | 2.9 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | -4.1 | 4.7 | 19.9 | 8.2 | 8.8 |
| Net Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 3.3 | 13.9 | 5.2 | 5.7 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.4 | 0 | - |
| Working Cap Days ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 799 | 306 | 227 | 187 | 108 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | -30 | 31 | 87 | 92 | 35 |
Valuation of Astal Laboratories - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'25 | Mar'26 |
|---|---|---|
| Sales | 64 | 250 |
| Operating Expenses ⓘ + | 51 | 229 |
| Operating Profit ⓘ | 13 | 21 |
| Operating Profit Margin (%) | 19.9% | 8.3% |
| Other Income ⓘ + | 0 | 0 |
| Interest ⓘ | 1 | 2 |
| Depreciation ⓘ | 0 | 1 |
| Profit Before Tax ⓘ | 12 | 18 |
| Tax ⓘ | 3 | 3 |
| Profit After Tax | 9 | 15 |
| PAT Margin (%) | 13.9% | 5.9% |
| Adjusted EPS (₹) | 9.1 | 3.5 |
| Dividend Payout Ratio (%) | 0% | 0% |
| PARTICULARS | Mar'25 | Mar'26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 32 | 332 | |||||||||
| Debt + | 13 | 48 | |||||||||
| Minority Interest | 0 | 0 | |||||||||
| Trade Payables | 11 | 124 | |||||||||
| Others Liabilities ⓘ | 7 | 14 | |||||||||
| Total Liabilities ⓘ | 63 | 519 | |||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 11 | 64 | |||||||||
| CWIP ⓘ | 0 | 0 | |||||||||
| Investments ⓘ | 0 | 203 | |||||||||
| Inventories | 15 | 68 | |||||||||
| Trade Receivables | 28 | 157 | |||||||||
| Cash Equivalents | 2 | 1 | |||||||||
| Others Assets ⓘ | 8 | 26 | |||||||||
| Total Assets ⓘ | 63 | 519 | |||||||||
| PARTICULARS | Mar'25 | Mar'26 |
|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -13 | -18 |
| Cash Flow From Investing Activity ⓘ + | -8 | -2 |
| Cash Flow From Financing Activity ⓘ + | 3 | 3 |
| Net Cash Flow ⓘ | -17 | -17 |
| PARTICULARS | Mar'25 | Mar'26 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 27.68 | 8.08 | ||||||||
| ROCE (%) | 25.74 | 9.15 | ||||||||
| Asset Turnover Ratio | 1.01 | 0.86 | ||||||||
| PAT to CFO Conversion(x) | -1.44 | -1.2 | ||||||||
| Working Capital Days | ||||||||||
| Receivable Days | 157.20 | 134.70 | ||||||||
| Inventory Days | 83.90 | 60 | ||||||||
| Payable Days | 81.70 | 112.10 | ||||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Annual reports
No annual reports available.
Concalls
No concalls available.
Astal Laboratories Ltd FAQs
The current trading price of Astal Laboratories on 04-Nov-2026 16:59 is ₹58.47.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Nov-2026 the market cap of Astal Laboratories stood at ₹224.5 Cr
The latest P/E ratio of Astal Laboratories as of 03-Nov-2026 is 23.06.
The latest P/B ratio of Astal Laboratories as of 03-Nov-2026 is 0.67.
The 52-week high of Astal Laboratories is ₹99.90 and the 52-week low is ₹49.99.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Astal Laboratories is ₹170 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Astal Laboratories Ltd is a below average quality company.
The key valuation ratios of Astal Laboratories Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Astal Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Astal Laboratories Ltd
No data to display
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now